Opinion Pieces Discuss Issues Surrounding Pharmaceutical Research, Drug Pricing
The Guardian: Drug-price hikes don’t lead to better cures. We must find another way forward
Philipp du Cros, infectious diseases specialist and head of the Manson Unit at Médecins Sans Frontières/Doctors Without Borders (MSF) U.K.
“…We must move beyond the idea that high prices are the only way to make drug development happen and stop swallowing the line that as long as we pay high prices, diseases that have until now been neglected will suddenly find the research backing they need. It’s simply not the case…” (9/24).
Al Jazeera America: We need publicly funded pharmaceutical research
Benjamin Spoer, PhD student at NYU’s College of Global Public Health
“…In an ironic twist, we can thank [Turing Pharmaceuticals CEO Martin] Shkreli for illuminating the disconnect between public health’s humane motives and biotech firms’ profit motives. Leaving drug development up to the market puts us at risk of prioritizing the health of people who can afford health care over the health of people who cannot. … An increase in public funding for pharmaceutical research would address the cause of these problems…” (9/24).
New York Times: Room for Debate: Should the Government Impose Drug Price Controls?
“…Does the government need to impose price controls to reduce the exorbitant cost of many drugs?” Multiple authors answer this question and others in several opinion pieces published as part of this New York Times “Room for Debate” (9/23).
The KFF Daily Global Health Policy Report summarized news and information on global health policy from hundreds of sources, from May 2009 through December 2020. All summaries are archived and available via search.